nanotech-investing Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
nanotech-investing Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
nanotech-investing Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
nanotech-investing Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
nanotech-investing Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
nanotech-investing Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
nanotech-investing Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
nanotech-investing Satellos to Participate in Four September Institutional and Retail Investor Conferences
nanotech-investing Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
